Meniere Disease Overview
Learn About Meniere Disease
Ménière disease is a disorder of the inner ear that affects balance and hearing. This condition is characterized by sudden episodes of extreme dizziness (vertigo), a roaring sound in the ears (tinnitus), a feeling of pressure or fullness in the ears, and fluctuations in hearing. Episodes are often associated with nausea and vomiting, and they can severely disrupt activities of daily living.
The cause of Ménière disease is unknown, although it probably results from a combination of environmental and genetic factors.
The prevalence of Ménière disease varies in different geographic regions and ethnic groups. It appears to be more common in people of European descent than in those with other backgrounds. In the United States, there are an estimated 615,000 people with Ménière disease, and more than 45,000 new cases are diagnosed each year.
Most cases of Ménière disease are sporadic, which means they occur in people with no history of the disorder in their family. A small percentage of all cases have been reported to run in families.
University Medical Associates Of The Medical University Of South Carol
Habib Rizk is an Otolaryngologist in Charleston, South Carolina. Dr. Rizk is rated as an Elite provider by MediFind in the treatment of Meniere Disease. His top areas of expertise are Meniere Disease, Vertigo, Benign Paroxysmal Positional Vertigo, Infant Hearing Loss, and Laryngectomy. Dr. Rizk is currently accepting new patients.
Johns Hopkins Outpatient Center
Neurotologist John Carey specializes in the health and diseases of the inner ear that affect both balance and hearing mechanisms. He is a national expert in superior canal dehiscence syndrome, Menière’s disease, vestibular migraine, acoustic neuromas and other causes of vertigo, and serves as chief of the Division of Otology, Neurotology and Skull Base Surgery in the Department of Otolaryngology–Head and Neck Surgery at the Johns Hopkins University School of Medicine. Dr. Carey earned a medical degree from Washington University School of Medicine and completed two years of training in general surgery at Virginia Mason Medical Center. This was followed by residency training in otolaryngology–head and neck surgery at University of Washington Medical Center and fellowship training in neurotology at the Johns Hopkins University School of Medicine. His research interests include superior canal dehiscence syndrome, Menière’s disease, vestibular implants, and the mechanisms of vestibular migraine. He has a particular interest in superior canal dehiscence syndrome, and, with Lloyd Minor, department director from 2003 to 2009, he helped develop the operation used to repair the superior canal. Dr. Carey has been funded by the National Institute on Deafness and Other Communication Disorders, part of the National Institutes of Health. He has authored or co-authored over 150 peer-reviewed publications, 10 book chapters, and 11 reviews. Dr. Carey is rated as an Elite provider by MediFind in the treatment of Meniere Disease. His top areas of expertise are Vertigo, Meniere Disease, Acoustic Neuroma, Mastoidectomy, and Endoscopy.
Penn Otorhinolaryngology - Head And Neck Surgery Radnor
Michael Ruckenstein is an Otolaryngologist in Radnor, Pennsylvania. Dr. Ruckenstein is rated as an Elite provider by MediFind in the treatment of Meniere Disease. His top areas of expertise are Schwannoma, Acoustic Neuroma, Meniere Disease, Gamma Knife Radiosurgery, and Myringotomy. Dr. Ruckenstein is currently accepting new patients.
Summary: The study will employ a stratified randomization method. Patients presenting to the Afyonkarahisar Health Sciences University Health Application and Research Center, Ear, Nose, and Throat Outpatient Clinic, with a definitive diagnosis of Meniere's disease, unilateral or bilateral involvement, and who consent to participate in the study will be divided into three groups. The control group will rece...
Summary: Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
Published Date: October 01, 2017
Published By: National Institutes of Health
